Mylan, Fujifilm Kyowa get EC nod for Humira biosimilar Hulio
The approval of Hulio is based on adoption of positive opinion by the Committee for Medicinal Products for Human Use (CHMP). The CHMP determined that development program, including
Bristol Myers Squibb (BMS) has reported full-year 2025 revenues of $48.2bn, essentially flat compared with $48.3bn in 2024.
The CLR 131 is an investigational radioiodinated PDC therapy, which exploits the tumor-targeting properties of the firm’s phospholipid ether (PLE) and PLE analogs to selectively deliver radiation to